Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Chemed (CHE)

Chemed Q2 diluted EPS falls 23.2% to $3.57; 2025 EPS guidance cut to $22.00-$22.30

Mixed Impact 4 of 5 earnings Written later

Chemed reported second-quarter 2025 revenue up 3.8% to $618.8 million, but GAAP diluted earnings per share fell 23.2% to $3.57. The company cut its full-year 2025 EPS guidance to $22.00 to $22.30 from $24.95 to $25.45, citing a larger Medicare Cap billing limitation at VITAS, and said VITAS CEO Nicholas M. Westfall is resigning, with Joel L. Wherley to succeed him.

Key points

  • Q2 2025 revenue rose 3.8% to $618.8 million; GAAP diluted EPS was $3.57, down 23.2%, and adjusted diluted EPS was $4.27, down 21.9%.
  • Full-year 2025 EPS guidance revised to $22.00 to $22.30, versus the previously issued $24.95 to $25.45.
  • VITAS estimates a $19 million Florida Medicare Cap billing limitation for the cap year ending September 30, 2025, and accrued $16.4 million in Q2 2025.
  • Nicholas M. Westfall resigns as Chairman and CEO of VITAS effective July 29, 2025, and will remain an Executive Vice President through December 1, 2025; Joel L. Wherley will succeed him as VITAS CEO.

The filing

CompanyChemed (CHE)
Form8-K, current report
Filed with the SECJul 29, 2025, 4:56 PM ET
Accession number0001562762-25-000181

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.